title: Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
abstract: Individuals with multiple sclerosis (MS) spasticity may experience a range of symptoms, such as bladder dysfunction, pain, impaired sleep quality and mobility restrictions that worsen as spasticity severity increases. In this review, the effects of Sativex(®) oromucosal spray on symptoms and functional impairment associated with MS-related spasticity were examined. Across Sativex studies, there was a clear trend for improvement in spasticity-associated symptoms that was more pronounced and sustained over time in Sativex responders. Meaningful symptomatic improvement was achieved within the recommended dosage limit of ≤12 sprays per day. In appropriate patients, Sativex has the potential to minimize the consequences of spasticity-related symptoms on quality of life and reduce the economic burden on healthcare systems.
authors.affiliation: Department of Neurology, University of Münster, Albert-Schweitzer Campus 1, 48149 Münster, Germany.
authors.forename: Sven G
authors.initials: SG
authors.lastname: Meuth
authors.forename: Carlos
authors.initials: C
authors.lastname: Vila
authors.forename: Kerry L
authors.initials: KL
authors.lastname: Dechant
mesh_terms: D002185:Cannabidiol; D002186:Cannabinoids / Q000627:therapeutic use*; D013759:Dronabinol; D004338:Drug Combinations; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology*; D010936:Plant Extracts / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects; D064232:Visual Analog Scale
chemical_list: D002186:Cannabinoids; D004338:Drug Combinations; D010936:Plant Extracts; D002185:Cannabidiol; D013759:Dronabinol; C587251:nabiximols
keywords: Sativex; multiple sclerosis; review; spasticity; symptom management